Molecular Docking: Shifting Paradigms in Drug Discovery

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2019 Sep 7

PMID 31487867

Citations 555

Authors

Luca Pinzi

Giulio Rastelli

Affiliations

Soon will be listed here.

Abstract

Molecular docking is an established in silico structure-based method widely used in drug discovery. Docking enables the identification of novel compounds of therapeutic interest, predicting ligand-target interactions at a molecular level, or delineating structure-activity relationships (SAR), without knowing the chemical structure of other target modulators. Although it was originally developed to help understanding the mechanisms of molecular recognition between small and large molecules, uses and applications of docking in drug discovery have heavily changed over the last years. In this review, we describe how molecular docking was firstly applied to assist in drug discovery tasks. Then, we illustrate newer and emergent uses and applications of docking, including prediction of adverse effects, polypharmacology, drug repurposing, and target fishing and profiling, discussing also future applications and further potential of this technique when combined with emergent techniques, such as artificial intelligence.

Citing Articles

Remedying SARS-CoV-2 through nature: a review highlighting the potentiality of herbs, trees, mushrooms, and endophytic microorganisms in controlling Coronavirus.

Patni B, Bhattacharyya M, Pokhriyal A, Pandey D Planta. 2025; 261(4):89.

PMID: 40089556 DOI: 10.1007/s00425-025-04647-8.

Investigating the pharmacological mechanisms of clopidogrel for carotid stenosis treatment based on network pharmacology and molecular docking techniques.

Wang X, Lu H, Xie J, Zhang C Clin Exp Med. 2025; 25(1):84.

PMID: 40087187 DOI: 10.1007/s10238-025-01602-5.

Diterpenes: Nature's Hidden Gems of Immunomodulation.

Almeida J, de Oliveira A, de Castro Alves C, Filho S, de Oliveira E, Zuliani J Int J Mol Sci. 2025; 26(5).

PMID: 40076871 PMC: 11900544. DOI: 10.3390/ijms26052250.

Exploring Herbal Compounds as Targeted Therapies for Breast Cancer: Insights from Network Pharmacology, Molecular Docking, MD Simulation, ADME-Toxicity and DFT Profiles.

Zhang H Iran J Pharm Res. 2025; 23(1):e153579.

PMID: 40066125 PMC: 11892757. DOI: 10.5812/ijpr-153579.

Computational pharmacology-based molecular mechanism investigation of cinnamaldehyde intervention in nephrotic syndrome.

Zeng Y, Li Q, Xie Z, Zhu J, Chen S, Sun J Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40064660 DOI: 10.1007/s00210-025-03925-2.

References

Nag S, Qin J, Wang W, Wang M, Wang H, Zhang R . Ginsenosides as Anticancer Agents: In vitro and in vivo Activities, Structure-Activity Relationships, and Molecular Mechanisms of Action. Front Pharmacol. 2012; 3:25. PMC: 3289390. DOI: 10.3389/fphar.2012.00025. View

Hassan A, Yoo S, Lee K, Yoon Y, Ryu H, Jeong Y . Repurposing mosloflavone/5,6,7-trimethoxyflavone-resveratrol hybrids: Discovery of novel p38-α MAPK inhibitors as potent interceptors of macrophage-dependent production of proinflammatory mediators. Eur J Med Chem. 2019; 180:253-267. DOI: 10.1016/j.ejmech.2019.07.030. View

Parenti M, Rastelli G . Advances and applications of binding affinity prediction methods in drug discovery. Biotechnol Adv. 2011; 30(1):244-50. DOI: 10.1016/j.biotechadv.2011.08.003. View

Coupez B, Lewis R . Docking and scoring--theoretically easy, practically impossible?. Curr Med Chem. 2006; 13(25):2995-3003. DOI: 10.2174/092986706778521797. View

Thomford N, Senthebane D, Rowe A, Munro D, Seele P, Maroyi A . Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery. Int J Mol Sci. 2018; 19(6). PMC: 6032166. DOI: 10.3390/ijms19061578. View

Moustakas D, Lang P, Pegg S, Pettersen E, Kuntz I, Brooijmans N . Development and validation of a modular, extensible docking program: DOCK 5. J Comput Aided Mol Des. 2006; 20(10-11):601-19. DOI: 10.1007/s10822-006-9060-4. View

Keiser M, Setola V, Irwin J, Laggner C, Abbas A, Hufeisen S . Predicting new molecular targets for known drugs. Nature. 2009; 462(7270):175-81. PMC: 2784146. DOI: 10.1038/nature08506. View

Grimes J, Hall D, Ashton A, Evans G, Owen R, Wagner A . Where is crystallography going?. Acta Crystallogr D Struct Biol. 2018; 74(Pt 2):152-166. PMC: 5947779. DOI: 10.1107/S2059798317016709. View

Ferreira L, Dos Santos R, Oliva G, Andricopulo A . Molecular docking and structure-based drug design strategies. Molecules. 2015; 20(7):13384-421. PMC: 6332083. DOI: 10.3390/molecules200713384. View

10.

Liu X, Zhu F, Ma X, Shi Z, Yang S, Wei Y . Predicting targeted polypharmacology for drug repositioning and multi- target drug discovery. Curr Med Chem. 2013; 20(13):1646-61. DOI: 10.2174/0929867311320130005. View

11.

Muhammed M, Aki-Yalcin E . Homology modeling in drug discovery: Overview, current applications, and future perspectives. Chem Biol Drug Des. 2018; 93(1):12-20. DOI: 10.1111/cbdd.13388. View

12.

Broccatelli F, Brown N . Best of both worlds: on the complementarity of ligand-based and structure-based virtual screening. J Chem Inf Model. 2014; 54(6):1634-41. PMC: 4068864. DOI: 10.1021/ci5001604. View

13.

Da C, Kireev D . Structural protein-ligand interaction fingerprints (SPLIF) for structure-based virtual screening: method and benchmark study. J Chem Inf Model. 2014; 54(9):2555-61. PMC: 4170813. DOI: 10.1021/ci500319f. View

14.

Baroni M, Cruciani G, Sciabola S, Perruccio F, Mason J . A common reference framework for analyzing/comparing proteins and ligands. Fingerprints for Ligands and Proteins (FLAP): theory and application. J Chem Inf Model. 2007; 47(2):279-94. DOI: 10.1021/ci600253e. View

15.

Luo H, Chen J, Shi L, Mikailov M, Zhu H, Wang K . DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome. Nucleic Acids Res. 2011; 39(Web Server issue):W492-8. PMC: 3125745. DOI: 10.1093/nar/gkr299. View

16.

Wilson G, Lill M . Integrating structure-based and ligand-based approaches for computational drug design. Future Med Chem. 2011; 3(6):735-50. DOI: 10.4155/fmc.11.18. View

17.

Kharkar P, Warrier S, Gaud R . Reverse docking: a powerful tool for drug repositioning and drug rescue. Future Med Chem. 2014; 6(3):333-42. DOI: 10.4155/fmc.13.207. View

18.

Xu X, Huang M, Zou X . Docking-based inverse virtual screening: methods, applications, and challenges. Biophys Rep. 2018; 4(1):1-16. PMC: 5860130. DOI: 10.1007/s41048-017-0045-8. View

19.

Kellenberger E, Muller P, Schalon C, Bret G, Foata N, Rognan D . sc-PDB: an annotated database of druggable binding sites from the Protein Data Bank. J Chem Inf Model. 2006; 46(2):717-27. DOI: 10.1021/ci050372x. View

20.

Kumar A, Zhang K . Application of Shape Similarity in Pose Selection and Virtual Screening in CSARdock2014 Exercise. J Chem Inf Model. 2015; 56(6):965-73. DOI: 10.1021/acs.jcim.5b00279. View